Relationship between igfbp3 methylation and prognostic and predictive response in stage ii and iii crc patients.

<p>(a) Disease-free survival of patients with stage ii and iii crc, according to <i>igfbp3</i> methylation status (high methylation, n = 73, (30.3%) low methylation, n = 168, (69.7%). (b) Disease-free survival of patients with stage ii disease, according to <i>igfbp3</i> methylation (high methylation, n = 45, (32.4%); low methylation, n = 94, (67.6%). (c) Disease-free survival of patients with stage ii and iii disease, in high <i>igfbp3</i> methylation tumors based on adjuvant chemotherapy (chemotherapy, n = 20, (22.5%); no chemotherapy, n = 69, (77.5%). (d) Disease-free survival of patients with stage ii and iii disease, in low <i>igfbp3</i> methylation tumors according to adjuvant chemotherapy (Chemotherapyc n = 83, (52.7%); NO Chemotherapy, n = 74, (47.2%).